Granted Patent
B2
US 12,478,676 · App. 18/187,248 · Granted Nov 25, 2025
Method of imaging
Assignee:
Exact Therapeutics AS
A61K41/0047A61K9/0009A61K9/1075A61K9/16A61K9/19A61K31/337A61K31/454A61K31/475A61K31/506A61K31/517A61K31/52A61K31/5377A61K31/704A61K31/7068A61K41/0028A61K49/0078A61K49/223A61L24/001A61L24/0015A61P7/04A61L2300/418A61L2300/45A61L2300/62A61L2430/36
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to a method of imaging, involving administration of a bi-phasic formulation followed by application of high frequency sound waves to identify a region of interest. Following identification, a phase shift of the bi-phasic formulation may be activated by a second administration of high frequency sound waves such that gaseous components of the bi-phasic formulation are enlarged and localised at the region of interest.
Claims (15)
1 . A method of high frequency sound wave imaging control of agent delivery to a subject, the method comprising:
administering a two-component, bi-phasic formulation and a separate therapeutic agent to the subject, wherein the therapeutic agent is selected from the group consisting of genes, chemotherapeutics and immunotherapeutics;
imaging a plurality of gaseous components of the bi-phasic formulation to identify a region of interest within said subject;
activating a phase shift of a vaporous component of the bi-phasic formulation by a first high frequency sound wave application of the region of interest, such that individual gaseous components are enlarged by the vaporous component to give enlarged individual gaseous components localised at the region of interest;
applying a second high frequency sound wave to the region of interest to oscillate the enlarged gaseous components; and
analysing the acoustic signature produced by the enlarged gaseous components to quantify the amount of therapeutic agent delivered,
wherein the therapeutic agent is delivered separately from the bi-phasic formulation, and wherein the first high frequency is different from the second high frequency and wherein the second high frequency sound wave comprises a frequency in the range of 0.05 to 1 MHz.
2 . The method of claim 1 , wherein the acoustic signature is analyzed by means of computer processing.
3 . The method of claim 2 , wherein analyzing the acoustic signature comprises quantifying the number of stationary phase shift contrast echoes per unit of tissue.
4 . The method of claim 1 , wherein individual enlarged gaseous components have a diameter of 10 μm or more.
5 . The method of claim 1 , wherein the therapeutic agent is delivered after the bi-phasic formulation.
6 . The method of claim 1 , wherein the bi-phasic formulation comprises an oil component having an opposite surface charge from the gaseous component.
7 . The method of claim 6 , wherein the oil component comprises a partially halogenated hydrocarbon.
8 . The method of claim 1 , wherein the gaseous component comprises sulphur hexafluoride.
9 . The method of claim 1 , wherein the first and second high frequency sound waves comprise a mechanical index below 0.7.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 28, 2023
From: HEALEY, ANDREW JOHN; SONTUM, PER CHRISTIAN; KVALE, SVEIN
To: PHOENIX SOLUTIONS AS
Reel/Frame 063129/0730 →
CHANGE OF NAME
Recorded Mar 28, 2023
From: PHOENIX SOLUTIONS AS
To: EXACT THERAPEUTICS AS
Reel/Frame 063174/0705 →
Priority Claims (1)
NO 20131293
· Sep 27, 2013
· national
Continuity (2)
Division
15024265
References Cited (100)
US 20040081623A1
· Eriksen et al.
· 2004
[cited by applicant]
US 20070178047A1
· Kawabata
· 2007
[cited by applicant]
US 20100298709A1
· Needles
· 2010
[cited by examiner]
US 20160243234A1
· Healey
· 2016
[cited by applicant]
US 20230211020A1
· Kvale et al.
· 2023
[cited by applicant]
US 20230218760A1
· Healey et al.
· 2023
[cited by applicant]
US 20230233681A1
· Healey et al.
· 2023
[cited by applicant]
US 20240216549A1
· Sontum et al.
· 2024
[cited by applicant]
US 20240269489A1
· Kvåle et al.
· 2024
[cited by applicant]
US 20240358984A1
· Kvåle et al.
· 2024
[cited by applicant]
US 20240359037A1
· Sontum et al.
· 2024
[cited by applicant]
CN 108815725A
· 2018
[cited by applicant]
EP 0727225A3
· 1997
[cited by applicant]
EP 1842560
· 2007
[cited by applicant]
EP 2468191A1
· 2012
[cited by applicant]
EP 2521593B1
· 2012
[cited by applicant]
JP 2005168312
· 2005
[cited by applicant]
JP 2007197403
· 2007
[cited by applicant]
JP 2008526785
· 2008
[cited by applicant]
WO WO1994016379A1
· 1994
[cited by applicant]
WO WO1998001732A1
· 1998
[cited by applicant]
WO WO9817324
· 1998
[cited by applicant]
WO WO9817324A2
· 1998
[cited by examiner]
WO WO1998051284A1
· 1998
[cited by applicant]
WO WO9939738
· 1999
[cited by applicant]
WO WO9953693
· 1999
[cited by applicant]
WO WO9953963
· 1999
[cited by applicant]
WO WO9953965
· 1999
[cited by applicant]
WO WO1999053963A1
· 1999
[cited by applicant]
WO WO9953963A1
· 1999
[cited by examiner]
WO WO2005063306
· 2005
[cited by applicant]
WO WO2015047103
· 2015
[cited by applicant]
WO WO2017080481
· 2017
[cited by applicant]
WO WO2018126322
· 2018
[cited by applicant]
WO WO2019094802
· 2019
[cited by applicant]
WO WO2020115491
· 2020
[cited by applicant]
WO WO2021045485
· 2021
[cited by applicant]
WO WO2021080438
· 2021
[cited by applicant]
WO WO2021118783
· 2021
[cited by applicant]
WO WO2021224921
· 2021
[cited by applicant]
WO WO2022069377
· 2022
[cited by applicant]
International Search Report and Written Opinion of PCT/NO2014/050177, Dated Jan. 15, 2015, in 11 pages.
[cited by applicant]
International Search Report and Written Opinion of PCT/NO2020/050260 dated Feb. 11, 2021 in 10 pages.
[cited by applicant]
Åslund, Andreas K.O. et al “Efficient Enhancement of Blood-Brain Barrier Permeability Using Acoustic Cluster Therapy (ACT)”, Theranostics 2017, vol. 7, Issue 1, doi: 10.7150/thno.16577.
[cited by applicant]
Dimcevski, Georg et al “A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer”, Journal of Controlled Release, 2016, vol. 243, pp. 172-181, http://dx.d…
[cited by applicant]
Kotopoulis, Spiros et al “Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma”, Journal of Controlled Release…
[cited by applicant]
Miller et al., “Bioeffects Considerations for Diagnostic Ultrasound Contrast Agents”, Journal of Ultrasound Med 2008; vol. 27, pp. 611-632.
[cited by applicant]
Nigel Bush et al “Acoustic Cluster Therapy displays theranostic capability in enhancing the effectiveness of liposomal doxorubicin treatment of human triple negative breast cancer in mice”, 2019 IEEE International Ultra…
[cited by applicant]
Postema et al., “Contrast-enhanced and Targeted Untrasound”, World Journal of Gastroenterol, Jan. 7, 2022, vol. 17, pp. 28-41.
[cited by applicant]
Schultz Christopher W et al: Selecting the Optimal Parameters for Sonoporation of Pancreatic Cancer in a Pre-Clinical Model 2019 IEEE International Ultrasonics Symposium (IUS), IEEE, Oct. 6, 2019 (Oct. 6, 2019), pp. 328…
[cited by applicant]
Van Wamel, Annemieke et al “Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacyof paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice”, Journal of Controlled Release, 2016, vol. …
[cited by applicant]
Notification of Reasons for Rejection issued Jun. 3, 2019 in corresponding Japanese Patent Application No. 2016-545714 with English language translation.
[cited by applicant]
Aoki et al., “Image of tumor metastasis and inflammatory lymph node enlargement by contrast-enhanced ultrasonography,” Word Journal of Radiology, Dec. 28, 2011, pp. 298-305.
[cited by applicant]
Beccaria et al., “Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits,” Journal of Neurosurgery, vol. 124, No. 6, Jun. 1, 2016, pp. 160…
[cited by applicant]
Brighi, “MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma,” Neuro-Oncology Advances, vol. 2, No. 1, Mar. 5, 2020 in 12 pages.
[cited by applicant]
Bulner et al., “Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles,” Ultrasound in Medicine and Biology, vol. 45, No. 2, Nov. 15, 2018, pp. 500-512.
[cited by applicant]
Bush et al., “Acoustic Cluster Therapy displays theranostic capability in enhancing the effectiveness of liposomal doxorubicin treatment of human triple negative breast cancer in mice,” 2019 IEEE International Ultrasoni…
[cited by applicant]
Bush et al., “Theranostic Attributes of Acoustic Cluster Therapy and Its Use for Enhancing the Effectiveness of Liposomal Doxorubicin Treatment of Human Triple Negative Breast Cancer in Mice,” Frontiers in Pharmacology,…
[cited by applicant]
Bush et al., “Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice,” Frontiers in Pharmacy, vol. 10, Nov. 19, 2019 in 14 pages.
[cited by applicant]
Bush et al., “Ultrasound, optical and photoacoustic imaging of Acoustic Cluster Therapy enhanced delivery to human tumors in mice, ” 2019 IEEE International Ultrasonics Symposium, Oct. 6, 2019, pp. 1556-1559.
[cited by applicant]
Carpentier et al., “Clinical trial of blood-brain barrier disruption by pulsed ultrasound,” Science Translational Medicine, vol. 8, No. 343, Jun. 15, 2016 in 8 pages.
[cited by applicant]
Chen et al., “Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study,” Journal of Translational Medicine, vol. 13, No. 1,…
[cited by applicant]
Chen et al., “Theranostic Strategy of Focused Ultrasound Induced Blood-Brain Barrier Opening for CNS Disease Treatment,” Frontiers in Pharmacology, vol. 10, Feb. 7, 2019 in 14 pages.
[cited by applicant]
Curley et al., “Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities,” Theranostics, vol. 7, No. 15, Jan. 1, 2017, pp. 3608-3623.
[cited by applicant]
Goldwirt et al., “Enhanced brain distribution of carboplatin in a primate model after blood-brain barrier disruption using an implantable ultrasound device,” Cancer Chemotherapy and Pharmacology, Springer Verlag, vol. 7…
[cited by applicant]
Jordao et al., “Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-? Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease,” Plos One, vol. 5, No. 5, May 1, 2010 in 8 pages.
[cited by applicant]
Kinoshita et al., “Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound,” Biochemical and Biophysical Research Communications, vol. 340, No. 4, Feb. 24, 2006, pp. 1085-1090.
[cited by applicant]
Mainprize et al., “Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study,” Scientific Reports, vol. 9, No. 1, Dec. 1, 2019 in 7 pages.
[cited by applicant]
Ng et al., “Abstract A099: Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma,” Molecular Cancer Therapeutics, vol.…
[cited by applicant]
Sontum et al., “Acoustic Cluster Therapy—A Novel Approach for Ultrasound Mediated Targeted Drug Delivery: Technology Basics and Proof of Concept,” ResearchGate, Jan. 1, 2016.
[cited by applicant]
Sontum et al., “Acoustic Cluster Therapy (ACT)—A novel concept for ultrasound mediated, targeted drug delivery,” International Journal of Pharmaceutics, vol. 495, No. 2, Nov. 30, 2015, pp. 23-30.
[cited by applicant]
Timko et al., “Remotely triggerable drug delivery systems”, Adv Mater. Nov. 24, 2010;22(44): 4925-4943.
[cited by applicant]
Van Wamel et al., “Acoustic Cluster Therapy (ACT): a novel concept for targeted drug delivery—In vivo Characteristics and Proof of Principle,” ResearchGate, Jan. 1, 2015.
[cited by applicant]
Van Wamel et al. “Acoustic Cluster Therapy (ACT)—pre-clinical proof of principle for local drug delivery and enhanced uptake,” Journal of Controlled Release, vol. 224, Jan. 13, 2016, pp. 158-164.
[cited by applicant]
Wei et al., “Focused Ultrasound-Induced Blood-Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A preclinical Study,” Plos One, vol. 8, No. 3, Mar. 1, 2013 in 10 pages.
[cited by applicant]
Zhang et al., “Focused-ultrasound Mediated Anti-Alpha-Synuclein Antibody Delivery for the Treatment of Parkinson's Disease,” 2018 IEEE International Ultrasonics Symposium, Oct. 22, 2018, pp. 1-4.
[cited by applicant]
Zheng et al., “Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma,” Nanomedicine, vol. 13, No. 3, Feb. 1, 2018, pp. 297-311.
[cited by applicant]
Combined Search and Examination Report received in UK Patent Application No. GB2104590.1 dated Sep. 27, 2021 in 6 pages.
[cited by applicant]
Combined Search and Examination Report received in UK Patent Application No. GB2105691.6 dated Oct. 7, 2021 in 5 pages.
[cited by applicant]
Andersen et al., “A harmonic dual-frequency transducer for acoustic cluster therapy.” Ultrasound Med Biol. Sep. 1, 2019;45(9):2381-2390.
[cited by applicant]
Argenziano et al., Vancomycin-loaded nanobubbles: A new platform for controlled antibiotic delivery against methicillin-resistant
[cited by applicant]
Carter et al., “Immune-oncology agents for cancer therapy.” Pharm. J. May 2020;304(7937): S2-S27.
[cited by applicant]
Castle et al., “Ultrasound-mediated targeted drug delivery: recent success and remaining challenges”. Am J Physiol Heart Circ Physiol. Feb. 2013;304(3):H350-7.
[cited by applicant]
Healey et al. “Acoustic cluster therapy: in vitro and ex vivo measurement of activated bubble size distribution and temporal dynamics,” Ultrasound in Med Biol. May 1, 2016;42(5): 1145-6611.
[cited by applicant]
Kooiman et al. Ultrasound-responsive cavitation nuclei for therapy and drug delivery. Ultrasound Med Biol. Jun. 1, 2020;46(6):1296-1325.
[cited by applicant]
Kurdziel et al., “Human dosimetry and preliminary tumour distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT”. J Nucl Med. Sep. 1, 2011;52(9):1339-1345.
[cited by applicant]
Lattwein et al., Sonobactericide: an emerging treatment strategy for bacterial infections. Ultrasound Med Biol. Feb. 1, 2020;46(2):193-215.
[cited by applicant]
Ryman et al., “Pharmacokinetics of monoclonal antibodies”. CPT Pharmacometrics Syst Pharmacol. Sep. 2017;6(9):576-588.
[cited by applicant]
Sontum et al., “Acoustic Cluster Therapy—A Novel Approach for Ultrasound Mediated Targeted Drug Delivery: Technology Basics and Proof of Concept”. In submitted to 21st European Symposium on Ultrasound Contrast Imaging, …
[cited by applicant]
Van Wamel et al., Ultrafast microscopy imaging of acoustic clustere therapy bubbles: Activation and oscillation. Ultrasound in Med Biol. Sep. 1, 2022;48(9): 1840-1857.
[cited by applicant]
Wang et al., “Experimental study of tumor therapy mediated by multimodal imaging based on a biological targeting synergistic agent,” Intl J Nanomed. Mar. 17, 2020: 1871-1888.
[cited by applicant]